How is Gilead Sciences (GILD) doing?

Gilead Sciences is a company in the drug manufacturers, general industry, based in Foster City, CA, worth $187.4B. Here is how its shares and business compare with the rest of the market, and where it shows up on our dashboards.

Updated Oct 9, 2026

P3 score

Weak

Gilead Sciences shares are up 28% over the past year, 11 points ahead of the S&P 500. Its type is Hot Hand. Among large US stocks and funds it ranks in the 78th percentile on market beat, the 6th on staying power and the 56th on business growth. It appears on 7 of our dashboards.

$151.17+28% in a yearWorth $187.4B

Compare with ABBV · BMY · MRK · LLY · AMGN · REGN

Financials, earnings and news on Stox ›

Past year

The past year

Price against the S&P 500, each set to $100 a year ago. Score is its weekly rank against the market. Select a tile for that score month by month.

GILD against the S&P 500, past year

$100 a year ago. Gilead Sciences +28%, the S&P 500 +16%.

GILDS&P 500

What kind of stock is it?

Its type on Stox Atlas, from its four scores: beating or lagging the market, a steady or erratic rank, a growing or slowing business, and whether buyers or sellers lead.

Hot Hand

BeatingErraticGrowingBought

Beating the market on a growing business with buyers adding, but its rank swings from week to week.

NovDecJanFebMarAprMayJunJulAugSepNow

Hot Hand since Jul; Turning Up before that.

Also Hot Hand (59 in all): DXCM · GMED · HALO · LH · NVST · ABBV

EmbracedToppingAccumulatingRejectedStable rankBellwetherDistribution TopCoiled SpringWallflowerHolding rankFaith TradeRolling OverBottom FishedSleepy StapleUnsteady rankHot HandChurning WinnerTurning UpShow-Me GrowerBouncy rankSpeculative PopExhausted RallyFalling KnifeBroken Year

How is it doing against its group?

Its group is Health care, 86 large US stocks and funds whose prices tend to move together. Tools, biotech and large-cap pharma — defensive growth.

GILD, past year+28%29 of 86 in the group

Rest of the group+20%equal-weighted

S&P 500+16%past year

Gilead Sciences is +28% over the past year, against +20% for the rest of the group and +16% for the S&P 500. It ranks 29th of 86 in Health care.

GILDRest of the group

Best in the groupRVMD Revolution Medicines+297%ILMN Illumina+184%NTRA Natera+133%

Worst in the groupPODD Insulet−57%BSX Boston Scientific−56%RARE Ultragenyx−50%

Its closest rivalsABBV AbbVie+20%BMY Bristol Myers Squibb+33%MRK Merck &+69%LLY Lilly (Eli)+39%AMGN Amgen+41%

Health care on Stox ›

How much does it move?

Its typical daily move, against its own past year, the market and other large stocks. Swings describe risk, not direction.

About usual Gilead Sciences typically moves 2.4% in a day, about usual for it, and it swings less than 71% of large US stocks.

Typical day2.4%about $3.56 a share

Its usual2.6%about usual, 0.9× its year’s average

Against the S&P 5002.3×the index’s typical day is 1.1%

Unusual day±4.7%twice its typical day

Deepest fall, past year−22%now 3% below its high

In the S&P’s down weeks5%of the index’s fall, three years; beta 0.3

Typical daily move (ATR)Its year’s average 2.56%

GILD on our dashboards

Every question where Gilead Sciences appears, in the order of the home page, with its reading and place in that table. Select a question to open it with GILD highlighted. Select a column to sort.

Question	Reading	Place	Details
What moved today, and why? What’s leading	90Unusual	25 of 30	Today +2.8% · × normal day 1.2×
Which stocks climb with the least drama? Leading stocks	82Smooth	34 of 60	Return per swing 1.00 · Return a year +26% · Volatility 26%
Which companies earn the most on their capital? Business quality	95Excellent	20 of 60	Return on capital 21% · Gross margin 79% · Cash margin 34%
Whose cash flow backs up their earnings? Business quality	99Backed	7 of 60	3 years 300% · Free cash flow $13.2B
Which companies get the most from each employee? Business quality	90Lean	46 of 60	Revenue / employee $1.7M · Profit / employee $523K · Value / employee $11.5M
Which companies invest the most in research? Business quality	83Heavy	33 of 60	R&D / revenue 19.9% · R&D a year $6.1B · R&D, 1Y +3%
Which companies could struggle with their debt? Value	97Losing money	10 of 60	Interest cover -1.5x · Net debt / EBITDA 36.3x · Interest a year $998.0M

Go deeper on Stox

GILD’s full profile: financial statements, earnings and analysts’ estimates, valuation against its sector, recent news with a summary, and its scores in detail.

Open GILD on Stox ›All 16 types on Atlas ›Its group on Stox ›

How to read this page

How it’s measured. Scores from Stox rank the stock against about 1,200 S&P 500, Nasdaq-100 and Russell 1000 stocks and popular funds, where 100 is best; market beat and staying power use prices, business growth uses revenue, margins and cash flow. Readings on other dashboards come from this site’s pages.

Sources. Daily prices and company financial statements from Financial Modeling Prep; scores and co-movement groups from Stox.

Scores are percentiles: 80 means the stock ranks above 80% of the others on that measure. They describe the recent past and are not advice or a forecast.

Its type follows Stox Atlas: each of the four scores is split at 50. “Steady” means its rank has held, high or low, so it says nothing on its own about direction.

Its group is the cluster of large US stocks whose prices have moved together over five years, with the market’s own moves taken out. The typical daily move is the average true range over 14 days, a measure of how far the price travels in a day including overnight gaps.

For financial statements, earnings and news, see GILD’s full profile on Stox.

This page is information, not investment advice. About our data and methods ›

Full profile on Stox ›Health care stocks ›ABBV · AbbVie ›BMY · Bristol Myers Squibb ›MRK · Merck & ›LLY · Lilly (Eli) ›